API-CAT Trial: Evaluating Low-Dose Apixaban for Cancer-Associated Thrombosis Introduction The API-CAT trial is a groundbreaking study designed to evaluate whether a reduced dose of apixaban (2.5 mg twice daily) is as effective as the standard full-dose regimen (5 mg twice … Read More
Oncology
AMBASSADOR Trial: Adjuvant Pembrolizumab in Urothelial Carcinoma
The AMBASSADOR trial is a phase 3 randomized clinical trial aimed at evaluating whether pembrolizumab as adjuvant therapy is more effective than observation in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery. Study Details: Inclusion Criteria: Primary Outcome: Secondary … Read More
LMS04 Trial: Doxorubicin-Trabectedin in Leiomyosarcoma
LMS04: Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma Published in: New England Journal of MedicineAuthors: Pautier P et al.Publication Year: 2024Source: N Engl J Med 2024; 391:789-799 Objective of the Study:This trial, LMS04, aimed to refine the treatment strategy for patients … Read More
SOURCE Trial: Sorafenib in Portal Vein Tumor Thrombus
Here’s the extracted information from the provided visual abstract: SOURCE Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus Study Design: Objective: Participants: Intervention Groups: Primary Outcome: Secondary Outcomes: Conclusion: Citation: This summary captures the key points from the … Read More
CheckMate 77T Trial: Nivolumab in Lung Cancer
CheckMate 77TPerioperative Nivolumab in Resectable Lung Cancer Design: Objective: Patients: Inclusion criteria: Exclusion criteria: Comparison: Primary Outcome: Secondary Outcomes: Conclusion: Reference: This data highlights the key points of the CheckMate 77T trial, comparing the outcomes of perioperative nivolumab combined with … Read More
PAPILLON Trial: Amivantamab in Lung Cancer
Year: 2023 Title: PAPILLON Subtitle: Amivantamab plus Chemotherapy in NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Type of Trial: A Randomized, Open-label Phase 3 trial Objective: To compare the efficacy, as demonstrated by progression-free survival (PFS), in … Read More
NADIM II Trial: Nivolumab in Lung Cancer
Objective: To examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone. Inclusion Criteria: Exclusion Criteria: Participants: 86 Patients Treatment Groups: Primary Outcome: Secondary Outcomes: … Read More
LIBRETTO-531 Trial: Selpercatinib in Medullay Thyroid Cancer
Objective: To determine if the study drug selpercatinib is safer and more effective compared to standard treatment in participants with RET-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. … Read More
LIBRETTO-431 Trial: Selpercatinib in NSCLC
Objective: To determine if the study drug selpercatinib, compared to a standard treatment, is effective and safe in participants with RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Inclusion Criteria: Participants: … Read More
CodeBreak 300 Trial: Sotorasib + Panitumumab in CRC
Year: 2023 Title: CodeBreaK 300 Subtitle: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C Type of Trial: A phase 3 randomized, open-label, active-controlled trial Objective: To compare progression-free survival in previously treated participants with KRAS G12C mutated … Read More